share_log

Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $6 Price Target

Benzinga ·  Dec 19, 2023 12:10

Cantor Fitzgerald analyst Kristen Kluska reiterates ADMA Biologics (NASDAQ:ADMA) with a Overweight and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment